Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy – a retrospective cohort study

1. OBRISCA B., ISMAIL G., JURUBITA R., BASTON C., ANDRONESI A., MIRCESCU G. Antiphospholipase A2 Receptor Autoantibodies: A Step Forward in the Management of Primary Membranous Nephropathy. Biomed Res Int. 2015;2015:249740.10.1155/2015/249740463037226576418Search in Google Scholar

2. BECK L.H. JR., BONEGIO R.G., LAMBEAU G., BECK D.M., POWELL D.W., CUMMINS T.D., et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11–21.10.1056/NEJMoa0810457276208319571279Search in Google Scholar

3. SVOBODOVA B., HONSOVA E., RONCO P., TESAR V., DEBIEC H. Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrol Dial Transplant. 2013;28(7):1839–44.10.1093/ndt/gfs43923223223Search in Google Scholar

4. HOFSTRA J.M., BECK L.H. JR., BECK D.M., WETZELS J.F., SALANT D.J., Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2011;6(6):1286–91.10.2215/CJN.07210810310992321474589Search in Google Scholar

5. SEGARRA-MEDRANO A., JATEM-ESCALANTE E., CARNICER-CÁCERES C., AGRAZ-PAMPLONA I., SALCEDO M.T., VALTIERRA N., et al. Evolution of antibody titre against the M-type phospholipase A2 receptor and clinical response in idiopathic membranous nephropathy patients treated with tacrolimus. Nefrologia. 2014;34(4):491-7.Search in Google Scholar

6. KANIGICHERLA D., GUMMADOVA J., MCKENZIE E.A., ROBERTS S.A., HARRIS S., NIKAM M., et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int. 2013;83(5):940–8.10.1038/ki.2012.48623364522Search in Google Scholar

7. BECK L.H. JR, FERVENZA F.C., BECK D.M., BONEGIO R.G., MALIK F.A., ERICKSON S.B., et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol. 2011;22(8):1543-50.10.1681/ASN.2010111125314870921784898Search in Google Scholar

8. RAMACHANDRAN R., KUMAR V., SINGH N., KATARUKA M., RATHI M.,KOHLI H.S., et al. Utility of determining autoantibodies to M-type phospholipase A2 receptor in diagnosing primary membranous nephropathy: An ideal setting. Indian J Nephrol. 2017;27(5):413-415.10.4103/ijn.IJN_165_16559042528904444Search in Google Scholar

9. TOMAS N.M., BECK L.H. JR, MEYER-SCHWESINGER C., SEITZ-POLSKI B., MA H., ZAHNER G., et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371(24):2277–87.10.1056/NEJMoa1409354427875925394321Search in Google Scholar

10. KDIGO Clinical practice guideline for glomerulonephritis. Kidney Int 2012;2 (Suppl 2):186-197.Search in Google Scholar

11. DU Y., LI J., HE F., LV Y., LIU W., WU P., et al. The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: A meta-analysis. PLoS One. 2014;9(8):e104936.10.1371/journal.pone.0104936413815425136841Search in Google Scholar

12. HOFSTRA J.M., DEBIEC H., SHORT C.D., PELLÉ T., KLETA R., MATHIESON P.W., et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol. 2012;23(10):1735–43.10.1681/ASN.2012030242345846522956816Search in Google Scholar

13. BRENCHLEY P.E. Anti-phospholipase A2 receptor antibody and immunosuppression in membranous nephropathy: more evidence for pathogenicity of anti-phospholipase a2 receptor autoantibodies. J Am Soc Nephrol. 2015;26(10):2308-11.10.1681/ASN.2015020181458770825804283Search in Google Scholar

14. VAN DE LOGT A.E., HOFSTRA J.M., WETZELS J.F. Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-up. Kidney Int. 2015;87(6):1263-4.10.1038/ki.2015.3426024039Search in Google Scholar

15. GOPALAKRISHNAN N., ABEESH P., DINESHKUMAR T., MURUGANANTH S., SAKTHIRAJAN R., RAMAN G.S., et al. Prevalence of serum anti M-type phospholipase A2 receptor antibody in primary membranous nephropathy: A single center experience. Indian J Nephrol. 2016;26(4):257-61.10.4103/0971-4065.160334496468527512297Search in Google Scholar

16. LI X., WEI D., ZHOU Z., WANG B., XU Y., PAN J., et al. Anti-PLA2R Antibodies in Chinese patients with membranous nephropathy. Med Sci Monit. 2016;22:1630-6.10.12659/MSM.896090Search in Google Scholar

17. OH Y.J., YANG S.H., KIM D.K., KANG S.W., KIM Y.S. Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy. PLoS One. 2013;8(4):e62151.10.1371/journal.pone.0062151363739023637987Search in Google Scholar

18. HILL P.A., MCRAE J.L., DWYER K.M. PLA2R and membranous nephropathy: A 3-year prospective Australian study. Nephrology (Carlton). 2016;21(5):397-403.10.1111/nep.1262426369693Search in Google Scholar

19. ARDALAN M., GHAFARI A., HAMZAVI F., NASRI H., BARADARAN B., MAJIDI J., et al. Anti-phospholipase A2 receptor antibody in idiopathic membranous nephropathy: A report from Iranian population. J Nephropath. 2013;2(4):241-8.Search in Google Scholar

20. QIN W., BECK L.H. JR, ZENG C., CHEN Z., LI S., ZUO K., et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 2011;22(6):1137–43.10.1681/ASN.2010090967310373321566055Search in Google Scholar

21. RUGGENENTI P., DEBIEC H., RUGGIERO B., CHIANCA A., PELLÉ T., GASPARI F., et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol. 2015;26(10):2545-58.10.1681/ASN.2014070640458768825804280Search in Google Scholar

22. TIMMERMANS S.A., ABDUL HAMID M.A., COHEN TERVAERT J.W., DAMOISEAUX J.G., VAN PAASSEN P.; LIMBURG RENAL REGISTRY. Anti-PLA2R antibodies as a prognostic factor in PLA2R-related membranous nephropathy. Am J Nephrol. 2015;42(1):70-7.10.1159/00043723626344651Search in Google Scholar

23. POURCINE F., DAHAN K., MIHOUT F., CACHANADO M., BROCHERIOU I., DEBIEC H., et al. Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years. PLoS One. 2017;12(3):e0173201.10.1371/journal.pone.0173201533629428257452Search in Google Scholar

24. HOXHA E., THIELE I., ZAHNER G., PANZER U., HARENDZA S., STAHL R.A. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol. 2014;25(6):1357-66.10.1681/ASN.2013040430403336524610926Search in Google Scholar

25. RADICE A., TREZZI B., MAGGIORE U., PREGNOLATO F., STELLATO T., NAPODANO P., et al. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). Autoimmun Rev. 2016;15(2):146-54.10.1016/j.autrev.2015.10.00426527329Search in Google Scholar

26. BECH A.P., HOFSTRA J.M., BRENCHLEY P.E., WETZELS J.F. Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2014;9(8):1386–92.10.2215/CJN.10471013412340225035272Search in Google Scholar

27. LIU Y., LI X., MA C., WANG P., LIU J., SU H., et al. Serum anti-PLA2R antibody as a diagnostic biomarker of idiopathic membranous nephropathy: The optimal cut-off value for Chinese patients. Clin Chim Acta. 2018;476:9-14.10.1016/j.cca.2017.11.00629126817Search in Google Scholar

28. TAMPOIA M., MIGLIUCCI F., VILLANI C., ABBRACCIAVENTO L., ROSSINI M., FUMARULO R., et al. Definition of a new cut-off for the anti-phospholipase A2 receptor (PLA2R) autoantibody immunoassay in patients affected by idiopathic membranous nephropathy. J Nephrol. 2018;31(6):899-905.10.1007/s40620-018-0533-z30187382Search in Google Scholar